Fate Therapeutics rises on Lupus drug data
Wall Street Breakfast
00:00
Promising Advances in Lupus Treatment and Stock Surge
This chapter delves into the advancements made by Fate Therapeutics, particularly their Phase I study of FT819 for lupus which resulted in patient remission. The discussion includes the implications of this development on the company's stock performance and expectations for upcoming medical presentations.
Transcript
Play full episode
